IBT’s Phase 3 Trial for IBP-9414 Misses Primary Goals, but Shows Positive Secondary Results

Infant Bacterial Therapeutics (IBT) has announced that its Phase 3 clinical trial for the drug candidate IBP-9414 did not achieve statistical significance for the two primary endpoints. However, the study showed positive results for secondary endpoints. This news comes as a setback for IBT, which is developing IBP-9414 to treat a specific type of bacterial infection in infants. Despite the primary endpoint miss, the company remains optimistic about the potential of IBP-9414 based on the positive secondary results.